Spinal cord injury (SCI), which is characterized by excessive
inflammatory
cell infiltration and accumulation of oxidative substance, would severely
impede neurological functional recovery and lead to permanent and
profound neurologic deficits and even disability. Methylprednisolone
(MP) is the most commonly used clinical anti-inflammatory drug for
SCI treatment, but high doses are typically required that can cause
severe side effects. Here, we developed a carrier-free thioketal linked
MP dimer@rutin nanoparticles (MP2-TK@RU NPs) which can
achieve combined SCI treatment by coassembling reactive oxygen species
(ROS) cleavable MP dimers and rutin. This proposed nanodrug possesses
the following favorable advantages: (1) the carrier-free system is
easily accessible and has a high drug-loading capacity, which is preferred
by the pharmaceutical industry; (2) The ROS-cleavable linker increases
the efficiency of targeted drug delivery to the injury site; (3) Rutin,
a type of plant-derived natural flavonoid with good biocompatibility,
anti-inflammatory, and antioxidant properties, is codelivered to enhance
the therapy outcomes. The obtained MP2-TK@RU NPs exhibited
potent anti-inflammatory and antioxidative properties both in vitro and in vivo, demonstrating superior
locomotor function recovery and neuroprotective efficacy in rats with
SCI. This carrier-free nanodrug is anticipated to provide a promising
therapeutic strategy for clinical SCI treatment.